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Abstract
Ensuring quality has become a daily requirement in laboratories. In haemostasis, even more than in other
disciplines of biology, quality is determined by a pre-analytical step that encompasses all procedures, starting with
the formulation of the medical question, and includes patient preparation, sample collection, handling,
transportation, processing, and storage until time of analysis. This step, based on a variety of manual activities, is the
most vulnerable part of the total testing process and is a major component of the reliability and validity of results
in haemostasis and constitutes the most important source of erroneous or un-interpretable results.
Pre-analytical errors may occur throughout the testing process and arise from unsuitable, inappropriate or wrongly
handled procedures. Problems may arise during the collection of blood specimens such as misidentification of the
sample, use of inadequate devices or needles, incorrect order of draw, prolonged tourniquet placing, unsuccessful
attempts to locate the vein, incorrect use of additive tubes, collection of unsuitable samples for quality or quantity,
inappropriate mixing of a sample, etc. Some factors can alter the result of a sample constituent after collection
during transportation, preparation and storage.
Laboratory errors can often have serious adverse consequences. Lack of standardized procedures for sample
collection accounts for most of the errors encountered within the total testing process. They can also have clinical
consequences as well as a significant impact on patient care, especially those related to specialized tests as these
are often considered as “diagnostic”. Controlling pre-analytical variables is critical since this has a direct influence on
the quality of results and on their clinical reliability. The accurate standardization of the pre-analytical phase is of
pivotal importance for achieving reliable results of coagulation tests and should reduce the side effects of the
influence factors. This review is a summary of the most important recommendations regarding the importance of
pre-analytical factors for coagulation testing and should be a tool to increase awareness about the importance of
pre-analytical factors for coagulation testing.
Keywords: Haemostasis assays, Pre-analytical phase, Coagulation assays, Recommendations, Dabigatran,
Idarucizumab, Microparticles, Centrifugation
Background
The term “pre-analytical phase” describes all actions and
aspects of the medical laboratory diagnostic procedure
that occurs prior to the analytical phase [1].
This phase is part of the total laboratory procedure
consisting of several stages and beginning with the
physician requesting the performance of a laboratory
investigation on a patient. It is the most vulnerable
part of the total testing process, where most laboratory
errors occur [2, 3]. It encompasses all procedures, starting
with the formulation of the medical question, and in-
cludes patient preparation, sample collection, handling,
transportation, processing, and storage until time of
analysis.
Pre-analytical laboratory errors can arise throughout the
pre-analytical phase, because this phase comprises a lot of
manual activities and accounts for most of the errors
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encountered within the testing process as a whole. Unsuit-
able, inappropriate or wrongly handled procedures during
collection and handling of specimens are very likely to
lead to pre-analytical errors [3].
Problems may arise during the collection of blood
specimens such as misidentification of the sample, use
of inadequate devices or needles, incorrect order of
draw, prolonged tourniquet placing, unsuccessful at-
tempts to locate the vein, incorrect use of additive tubes,
collection of unsuitable samples for quality (e.g. contam-
inated, haemolysed) or quantity (e.g. insufficient amount
of blood or inappropriate blood-to-anticoagulant ratio),
inappropriate mixing of a sample, etc. Some factors can
alter the result of a sample constituent after collection
during transportation, preparation and storage. The side
effects of such factors of influence can be reduced by
standardizing the pre-analytical process [4–6].
This review aimed at summarizing recommendations
with regard to the pre-analytical phase and provides
some guidance to reduce the effects of biological factors
that can have a significant impact on patient care.
Methods
A systematic review was conducted following the recom-
mendations of the French Study Group on Haemostasis
and Thrombosis (GFHT), the World Health Organization
(WHO), the Clinical and Laboratory Standards Institute
(CLSI) guidelines, the International Society on Throm-
bosis and Haemostasis (ISTH), the European Federation
of Clinical Chemistry and Laboratory Medicine (EFLM)
and the British Committee for Standard in Haematology
(BCSH) about the pre-analytical phase and the pre-
analytic variables which can have an impact on the quality
of medical laboratory results and about the procedures for
sample collection, processing, transportation, and storage
in haemostasis testing.
The development of the present literature review was car-
ried out using the PubMed database records including ana-
lysis of references from selected articles from 1991 to 2016
based on the following key-words: ‘pre-analytical phase’,
‘pre-analytic variables’, ‘pre-analytical quality’, ‘preoperative/
pre-operative tests’, ‘order of draw’, ‘phlebotomy’, ‘screening
tests’, ‘routine tests’, ‘screening testing’, ‘hemostasis/haemosta-
sis’, ‘coagulation tests’, ‘bleeding history’, ‘preoperative bleed-
ing questionnaire’, ‘preoperative evaluation’, ‘bleeding risk’,
‘haemorrhage/hemorrhage’, ‘surgery’, ‘von Willebrand dis-
ease’, ‘von Willebrand factor’, ‘inherited bleeding disorders’,
‘bleeding score’, ‘quality’, standardization’, ‘collection of blood’,
‘sample collection’, ‘tourniquet’, ‘samples’, ‘transportation’,
‘preparation’, ‘storage’, ‘recommendations’, ‘discard tubes’, ‘acti-
vated partial thromboplastin time, PTT, aPTT’, ‘prothrom-
bin time, PT’, ‘international normalized ratio, INR’, ‘bleeding
time’, ‘platelet count’, ‘platelet function testing’, ‘PFA-100’,
‘blood sampling’, ‘sample tubes’, ‘anticoagulant’, ‘order of
filling the tubes’, ‘sampling process’, ‘processing of samples’,
‘transportation of samples’, ‘centrifugation’, ‘storage condi-
tions’, ‘freezing’, ‘thawing’. Only articles in English or French
were analysed. The database was searched for studies, clin-
ical practice recommendations and literature reviews.
The findings of our search have been grouped into dif-
ferent subtopics. The first one is devoted to the clinical
history, bleeding score and physical examination to dem-
onstrate the importance of the patient’s history regarding
various diseases such as thrombotic diseases in case of
haemorrhagic diathesis or preoperative assessment. The
following chapters concern the sample collection and se-
quence of drawing blood. The last subtopics concern the
sampling process, transportation and storage conditions.
The first step before considering laboratory testing;
Clinical history and physical examination
Prior to any type of haemostatic testing a bleeding history
is a prerequisite for the diagnosis of any bleeding disorder
and should guide further laboratory investigations [7, 8].
If this is done diligently, it can be considered as one of
the best screening tests of the risk of bleeding [7, 9, 10]. It
allows the detection of pathology known to cause abnor-
mal primary haemostasis (malnutrition, haematologic dis-
ease, liver failure, etc.). In case of acquired haemostatic
disorders, family history can be seen as a family tree of the
types of haemorrhage observed as well as their spontan-
eous or provoked features. As far as a person’s bleeding
history is concerned, it is important to know the terms of
appearance of haemorrhages, their frequency and their
source, and whether bleeding is aggravated after taking as-
pirin and/or other medications like antiplatelet therapy,
NSAIDs, etc. Regarding the surgical and obstetrical his-
tory, it is important to note the number of interventions
that resulted in bleeding complications (new intervention
due to complication, transfusion, admission to intensive
care, etc.), but also the number of times that trauma was
not associated with haemorrhagic complications. Anteced-
ents of anemia, iron supplementation, hospitalization or
blood transfusion can also guide the clinician [11, 12]. The
patient’s blood group provides relevant information re-
lated to haemostatic activity (e.g. activity levels of VWF).
Patients with blood group O are known to have lower
levels of VWF. The presence of the H-antigen (O group)
promotes the cleavage of VWF by ADAMTS13 metallo-
protease, and, moreover, a higher hepatic clearance of
VWF [13, 14].
In order to prevent disturbing pre-analytical influences,
any interfering drugs should be administered after collect-
ing a blood sample. A record of all the drugs that the sub-
ject took during the week prior to testing should be
collected [15]. Treatment with desmopressin, in treating
or preventing bleeding episodes in patients with von
Willebrand disease, haemophilia A and platelet function
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defects, should be noted [16]. It is important to know if
the patient is pregnant. Pregnancy is associated with in-
crease in fibrinogen, factors VII, VIII, X, VWF, D-dimer
concentration and with increase in levels of prothrombin
fragments 1 + 2 and thrombin-antithrombin III com-
plexes. There is a decrease in physiological anticoagulants
manifested by acquired activated protein C (APC) resist-
ance. Free protein S is decreased secondary to increased
levels of its binding protein, the complement component
C4b [17–19]. The overall fibrinolytic activity is impaired
during pregnancy, but returns rapidly to normal following
delivery. This is largely due to placental derived plasmino-
gen activator inhibitor type 2 (PAI-2), which is present in
substantial quantities during pregnancy [19]. Microparti-
cles derived from maternal endothelial cells and platelets,
and from placental trophoblasts may contribute to the
procoagulant effect [19].
Hormonal contraceptives can be responsible for inter-
ferences in coagulation testing and may lead to increased
concentrations of fibrinogen, prothrombin and factors VII,
VIII and X, and reduction in coagulation inhibitors, such
as antithrombin (AT), protein S and tissue factor pathway
inhibitor (TFPI) [17, 20, 21]. Use of combined oral contra-
ceptives is associated with a three-to six-fold increased
risk of venous thrombosis. This increased risk depends on
the estrogen dose as well as the progestogen type of oral
contraceptives [22]. These changes tend to me more pro-
nounced in women taking third generation combined oral
contraceptives than on second generation [21]. Women
using combined oral contraceptives with the highest risk
of venous thrombosis (e.g. containing desogestrel, cyprot-
erone acetate or drospirenone), have lower levels of PS
and TFPI than women using the combined oral contra-
ceptive with the lowest risk of venous thrombosis (i.e.
contraceptives containing levonorgestrel) [22, 23].
Reduced concentrations of protein S can be caused by
functional impairment of this protein by differences in
modulation of its activity by other plasma proteins that
change during the oral contraceptives use or by changes
induced in the protein S molecule that impair its anti-
coagulant activity [24]. For platelet function assays, treat-
ment with drugs known to reversibly inhibit platelet
function (e.g. NSAIDs) should be stopped at least 3 days
before sampling, and treatment with drugs known to irre-
versibly inhibit platelet function (e.g. aspirin, thienopyri-
dines) should be stopped at least 10 days before sampling,
if possible [8, 15]. As it oftentimes impossible to stop all
medication before being sampled for coagulation studies,
drug-induced effects on platelet function should be
considered when interpreting results [15]. Treatment con-
tinuation is also sometimes recommended to assess the ef-
ficacy and safety of antithrombotic drugs [9].
The referring physician should also have done a
proper physical examination in order to detect signs of
coagulopathy. In case of primary haemostatic abnorma-
lities, it is common to seek a cutaneo-mucous type of
haemorrhage. Elements usually seen in haemorrhagic
syndrome are bruising, purpura, or haemarthrosis. In case
of testing for thrombophilia, signs of previous venous
thrombosis including post-thrombotic syndrome (venous
insufficiency, corona phlebectatica etc.) can be inform-
ative. Moreover, it is very important that the clinician and
the laboratory exchange all relevant information as much
as possible [25].
Bleeding score
To collect the bleeding history, in case of haemor-
rhagic diathesis or preoperative assessment of bleed-
ing risk, and to obtain the resulting bleeding score
(BS), standardized and validated clinical tools are ne-
cessary [10].
a) haemorrhagic diathesis: In an attempt to
standardize the diagnostic criteria of von Willebrand dis-
ease (VWD), the most prevalent congenital bleeding
disorder which occurs with equal frequency among men
and women and affecting up to 1% of the general popu-
lation, a BS has been developed [26]. This one is useful
for the identification of subjects requiring laboratory
evaluation for VWD and for assessing the clinical severity
of the disorder in patients with type 1 VWD [7, 27–29].
This BS, related to the number and the severity of bleed-
ing symptoms, is based on a standardized questionnaire
and used to evaluate haemorrhagic symptoms [7, 29]. The
questionnaire has proven to be useful for diagnostic pur-
poses, allowing the establishment of quantitative cut-offs
discriminating healthy subjects and carriers of VWD [7].
The BS is proposed as a predictor of clinical outcomes of
inherited VWD, and may also help to identify cases at
higher risk of frequent and severe bleeds requiring more
intensive prophylactic regimens [30].
Other BS have been developed for the large population
of patients with atrial fibrillation (AF) that require oral
anticoagulant therapy (e.g. HAS-BLED, ATRIA, ORBIT
risk scores, etc.) [31].
The combination of the standardized bleeding question-
naire and an interpretation grid has been referred to as a
Bleeding Assessment Tool (BAT) [7]. Although existing BS
have limitations (e.g. dependence on clinician interpretation
regarding patient recall, inability to distinguish among
bleeding events occurring at different anatomical sites, etc.)
their use is strongly encouraged, as BATs have proven valid-
ity in assessment of symptom severity and help identify pa-
tients needing further investigations [10, 32, 33].
To ensure reliability and reduce the time load, the
questionnaire should be performed by a physician or
other health professional experienced in assessing a
(mild) bleeding disorder (MBD), particularly in patients
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who have abnormal clotting screening test results requi-
ring invasive procedures or elective surgery [7, 34].
The ISTH/SSC Joint Working Group agreed to estab-
lish a single BAT to standardize the reporting of bleed-
ing symptoms which would be useful for both paediatric
and adult populations. More quantitative BATs have
been proposed to improve the diagnostic criteria for
MBD because most patients with an MBD do not show
a definitive bleeding history, and are difficult to distin-
guish from normal subjects [7].
This revised BAT could be more generally applicable to
the investigation of other inherited bleeding disorders with
variable expressivity (e.g. mild platelet function disorders)
to avoid the bias of subjective investigator evaluation of
haemorrhagic symptoms and to reduce the need for ex-
pensive laboratory investigations [7, 8, 29]. Even if the
ISTH-BAT has not been evaluated sufficiently in inherited
platelet function disorders to allow a firm recommenda-
tion of its use, it could also be potentially useful for the
diagnosis of platelet function disorders [32, 33].
b) pre-operative assessment: For preoperative investiga-
tions, some guidelines are available. Recently the French
Society of Anaesthesia and Intensive Care issued recom-
mendations for the prescription of routine preoperative
testing before a surgical or non-surgical procedure, re-
quiring any type of anaesthesia [9]. The aim of pre-
anaesthetic screening, based on detailed patient inter-
views and on physical examination, is to identify patients
with an increased risk of perioperative bleeding to min-
imise perioperative haemorrhagic complications.
Routinely haemostasis testing has very little thera-
peutic impact and lacks prognostic utility. Hence,
haemostasis testing should not be systematically used in
patients whose history and clinical examination results
do not suggest any haemostatic disorders. Conversely, in
patients with a positive history of haemorrhagic diath-
esis, haemostasis testing should be requested depending
on the suspected disease [9].
These recommendations are in line with those issued in
the United States and in the United Kingdom by the Na-
tional Institute for Health and Clinical Excellence (NICE).
Only the Italian SISET recommendations (Società Italiana
per lo Studio dell’Emostasi et della Trombosi) suggest per-
forming systematic haemostasis testing with aPTT, PT and
platelet count prior to any intervention, even in patients
with no bleeding diathesis history [9].
Variables during sample collection
During the pre-analytical phase, in case of haemostasis
testing for patients with a positive history of haemor-
rhagic diathesis, certain steps regarding the preparation
of patients and the execution of sampling (specimen col-
lection, transportation, sample preparation and storage)
are of special importance. Providing patients with the
appropriate instructions before blood sampling and
proper training of those persons involved in sampling
procedures can reduce or prevent negative influences on
laboratory results and their misinterpretation [4, 35].
In order to minimize misinterpretation of laboratory re-
sults, blood samples should be collected from fasting sub-
jects in the morning between 7 and 9 a.m. and from
subjects who have refrained from smoking for at least
30 min [4, 8, 15, 36, 37]. Consumption of caffeine should
be discouraged within the 2 h prior to sampling [4, 15].
Physical activity within the 2 h prior to sampling is not rec-
ommended. Blood samples should be collected after the
subject has rested for a short period (at least 5 min) [15].
Diet and drinking are major factors influencing a num-
ber of analyses. Before blood sampling, the disturbing in-
fluences of food and drink should be excluded. Patients
should not be studied after meals associated with a high
fat content, so as to avoid the formation of chylomicrons
in plasma, which will interfere with light transmission
aggregometry [15, 37]. A light meal does not influence
the laboratory coagulation tests. However, to completely
metabolize the lipids intake, sampling after at least 8 h
(better 12 h) fasting and reduced activity (bed rest) is
recommended [4, 38]. It is also advisable not to eat dark
chocolate [39].
Stress should be avoided under all circumstances (e.g.
restless child), because stress increases acute phase pro-
teins of which von Willebrand factor (VWF), factor VIII
and fibrinogen [40] are most important (in particular in
the workup for haemophilia or VWD). Smoking around
the time of phlebotomy enhances platelets aggregability,
and induces a procoagulant state in plasma [41, 42].
Studies have reported an increase in blood coagulability
but impaired fibrinolysis in habitual smokers when com-
pared with nonsmokers [42]. It seems that higher plasma
levels of fibrinogen and viscosity are the main contribu-
tors to higher coagulability found in smokers, whereas
the lower fibrinolytic potential is mainly attributed to an
increase in PAI-1 activity and possibly also a decrease in
tPA activity and lower plasminogen levels [41, 42].
Smokers may have impaired acute substance P-induced
endothelial release of active tPA in vivo related to im-
paired endothelial function, which suggests a possible
direct link among impaired endogenous fibrinolysis,
endothelial dysfunction, and arterial atherothrombosis in
smokers [42].
Caffeine enhances fibrinolytic potential as whole blood
fibrinolysis time is shortened and PAI-1 levels are de-
creased, whereas tPA activity increases after consump-
tion of coffee and such effects are blunted during
caffeine abstinence [42]. About dark chocolate, platelet
aggregation is modulated by a flavanol-independent
mechanism that is likely due to theobromine which is
containing by cocoa products [39].
Magnette et al. Thrombosis Journal  (2016) 14:49 Page 4 of 14
Physical activity may cause an increase in leukocyte
count and activation of coagulation (decrease of pro-
thrombin time (PT) and fibrinolysis). It can also activate
partial thromboplastin time (aPTT), cause an increase in
D-dimer, tissue plasminogen activator (tPA) and plas-
minogen activator inhibitor (PAI), an exercise-induced
adrenaline release on platelet aggregation and an in-
crease in platelets [4, 15, 36]. Strenuous exercise also
promotes the release of microparticles by platelets and
triggers a transient procoagulant condition, which is
mirrored by increased thrombin generation, platelet hy-
perreactivity, increased activity of clotting factors, com-
pounded by an increased fibrinolytic activity [41, 43].
Training in phlebotomy
Phlebotomy is the act of puncturing a vein for the
purpose of withdrawing blood and is one of the most
critical parts of the entire pre-analytical phase [44].
Training of phlebotomists is a pre-analytical challenge
and requires continuous educational updates as equip-
ment is changed in the healthcare institutions [45].
All staff members should be trained in phlebotomy, to
prevent unnecessary risk of exposure to blood and to re-
duce adverse events for patients [46]. If the phlebotomist
is a member of the laboratory staff, he/she will be aware
of the impact of the quality of sampling on the quality of
results. If he/she is external to the laboratory, the labora-
tory must provide all information necessary about good
sampling practices [6, 36].
Blood sampling
According to the recommendations of the EFLM, tube la-
belling must be done, before or after venipuncture, in the
presence of the patient. The phlebotomist should label
each drawn tube with the patient’s full name, patient’s date
of birth, identification number [6, 38]. Of course, the use
of prebarcode tubes may facilitate collecting this informa-
tion. The sampling equipment must be sterile and non-
pyrogenic. The expiry dates of the needle and the integrity
of the sterile seal should be checked. The phlebotomy pro-
cedure provided by the CLSI requires wearing gloves,
cleansing the venipuncture site and drying of skin before
applying the tourniquet and selecting the venipuncture
site and vein [47]. The venipuncture should be ideally col-
lected directly from a peripheral vein (antecubital vein). If
a tourniquet needs to be used, it should immediately be
released when the first tube starts to fill [48]. The diam-
eter of the needle should preferably be comprised between
19 and 22 gauge [34, 49].
It is important to take samples so as to reduce platelet
activation in-vitro and to restrict the use of the tourniquet
[15, 36, 49]. Extended tourniquet application might pro-
duce unnecessary venous stasis or in-vitro haemolysis,
which could introduce spurious and clinically meaningful
biases in the measurement of several haematologic param-
eters [47]. Hence, the tourniquet should be placed tightly
but less than one minute in order to prevent haemocon-
centration, increased fibrinogen and factors VII, VIII, XII
as well as activation of endothelial cells and therefore fi-
brinolysis [47, 48]. Some special coagulation assays, such
as those that measure thrombin generation markers (e.g.,
thrombin antithrombin complex (TAT) and prothrombin
fragment 1 + 2), should be drawn without the use of a
tourniquet because that may lead to spurious elevation of
these markers, particularly if the tourniquet is left in place
for more than one minute [5]. A quality laboratory man-
ager should verify the length of tourniquet application and
forearm clenching in order to eliminate this source of la-
boratory error and safeguard quality throughout the total
testing process [48].
Venipuncture may be necessary, on occasion, to obtain
blood from an existing vascular access device such as an
intravenous (IV) line or a central line [5]. If an IV line is
present, the sample site selected is distant from the line.
Butterfly devices and 23 gauge needles can be used on
patients with difficult veins (geriatrics, oncology and
paediatrics), provided that the tubing is short (length
<6 cm and air volume <150 μL) [36, 45].
However, owing to costs and the risk of obtaining un-
suitable samples, the use of butterfly needles and IV cathe-
ters has generally been discouraged, because haemolysis,
activation of the contact system, initiated by activation of
factor XII, can occur when blood comes into contact with
the surface of a biomaterial [2]. Blood samples should be
obtained in a relatively atraumatic fashion, and during col-
lection the blood should flow freely into the collection
container [4]. In case of difficult sampling, at least this in-
formation should be recorded for adequate interpretation
of haemostasis assays [50]. Blood sampling should be per-
formed without generating foam or bubbles in the sample
and with as little shear stress as possible [4].
The passage of blood through butterfly tubing and IV
catheters might cause increased haemostatic alterations
in comparison to blood collection using a conventional
straight needle, directly into the tube [2].
The direct transfer of blood specimens from syringes
to blood collection tubes by piercing of the rubber stop-
per of the tube is a practice that should be avoided. This
may cause haemolysis when cells under pressure from
the plunger collide with the tube wall [4].
The investigation of platelets is highly vulnerable to a
broad series of pre-analytical variables [8]. In particular,
the vacuum aspiration of blood into primary collection
tubes could have an influence on platelet function test-
ing. A syringe system permitting slow manual drawing
of blood may be superior [4]. For the Platelet Function
Analyser (PFA-100), which replaces the bleeding time in
many laboratories, the lower shear stress generated by
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manual aspiration of blood into the primary collection
tube would prevent spurious hyper-activation of plate-
lets, thus, preserving the integrity of their function for
subsequent testing on PFA-100 [8, 27, 51].
Optimally, blood sampling is done in the laboratory
performing the analyses, which allows for verifying many
of the above mentioned steps including when needed
getting additional data on medical history, medication,
fasting state etcetera. Patient identification and tube la-
belling are the most critical steps during phlebotomy,
providing an essential safety barrier to prevent patient
identity mix-up.
Labelling blood tubes in the absence of the patient is a
potentially life threatening error. According to CLSI, pa-
tient identification is the responsibility of the phlebot-
omist to ensure that blood is drawn from the individual
designated on the request form [6] (Table 1).
Sample tubes and anticoagulant
Blood samples for coagulation analyses should be drawn
into siliconized glass tubes, or plastic (polypropylene)
tubes [35, 49]. Vacuum tubes must be sealed and CE
marked [15, 36]. Care must be taken to follow manufac-
turer’s expiry dates. Sample tubes for haemostasis analyses
generally contain an anticoagulant. The CLSI guidelines
on the collection of blood specimens for coagulation
testing recommend the use of sodium citrate in 105–
109 mmol/L (3.2%) tubes. The use of mmol/L should be
preferred to %. The pH of the anticoagulated plasma
should be comprised between 7.3 and 7.45 [35, 36].
The vast majority of the samples should be collected
into trisodium citrate, buffered anticoagulant to help keep
the pH stable during processing and testing [15, 36]. The
anticoagulant effect of sodium citrate is attributed to its
ability to bind calcium, making the calcium unavailable to
promote clot formation [4]. However there may also be
higher citrate concentration (i.e., 3.8% or 129 mmol/L)
leading to greater calcium binding and longer clotting
times. Specimens collected in 3.8% buffered sodium citrate
may prolong the PT and aPTT and underestimate fibrino-
gen if the normal range is based on 3.2% citrated samples
[4, 47]. Due to the variation in clotting times and sodium
citrate concentration, the consensus recommendation
suggests that laboratories should standardize to one citrate
concentration and develop appropriate reference intervals
[4, 5, 35, 36, 47].
For some analyses, especially platelet function assays,
buffered citrate solution or other anticoagulants are
used. Citrate, theophylline, adenosine and dipyridamole
(CTAD) is a cocktail of additives that prevent in-vitro
platelet activation recommended for measurement of
platelet-activation markers such as β-thromboglobulin
or platelet factor 4 (PF4). These tubes allow for more re-
liable measurement of unfractionated heparin (UFH)
and are useful for the study of membrane glycoproteins
platelet by flow cytometry. They should be kept away
from light [36]. Sampling these tubes allows a delay in
analysis until 4 h before centrifugation [52].
It is easy to ensure that the anticoagulant is consistent
when working on the primary tube; vigilance is therefore
required in case of analysis performed on an aliquot [53].
Sequence of drawing blood
A standardized sequence of blood sampling must be
respected in order to avoid carry-over between tubes [3].
National and international (WHO, CLSI) guidelines
recommended that the order of draw of blood during
phlebotomy should be blood culture/sterile tubes, then
coagulation tubes, then plain tubes/gel tubes, then tubes
containing additives [3–5]. According to the CLSI, a first
discard tube (or a non-additive tube) is unnecessary for
routine coagulation assays [47]. A discard tube (or a cit-
rate tube if the sampling is difficult) must be drawn
when citrated plasma is obtained using butterfly systems
or other IV catheter devices because the air volume con-
tained in the tubing partially fills the vacuum tube, lead-
ing to insufficient filling of the tube with citrate. A
discard tube is also recommended when samples are
Table 1 Summary of key pre-analytical recommendations about
blood sampling
Blood sampling Use siliconized glass or plastic (polypropylene) tubes.
Blood samples should be drawn into 105–109 mmol/L
sodium citrate, buffered anticoagulant.
The pH of the anticoagulated plasma should be
comprised between 7.3 and 7.45.
Perform blood collection from fasting subjects in the
morning (between 7 and 9 a.m.).
The patient should be relaxed. Stress should be
avoided.
Label each drawn tube with the patient’s full name,
patient’s date of birth, identification number.
Collect venipuncture directly from a peripheral vein
(antecubital vein).
The diameter of the needle should preferably be
comprised between 19 and 22 gauge.
Release the tourniquet immediately when the first
tube starts to fill (<1 min).
The order of drawing blood during phlebotomy
should be blood culture/sterile tubes, then coagulation
tubes, then plain tubes/gel tubes, then tubes
containing additives.
Draw a discard tube when citrated plasma is obtained
using butterfly systems or other IV catheter devices.
Discard tube may be considered to ensure correct
filling of sample tubes for coagulation tests.
Ensure correct filling of tubes (>90% filling).
Respect the required ratio of sodium citrate to whole
blood (1:9).
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subject to platelet function analysis and for thrombin
generation measurements [2, 4, 8, 47].
Published studies have demonstrated that for routine
coagulation testing, the use of a discard tube is not ne-
cessary because there was no significant difference in the
aPTT and PT results between the first and second tubes
drawn [2, 4, 5, 36, 44, 54]. Some studies evaluated the
need for discard tubes in a variety of others coagulation
tests (e.g. fibrinogen, D-dimer, factors II, V, VII, VIII, IX,
X, XI, proteins C and S and AT, …) and suggested that
discard tubes are not necessary when drawing samples
for specialized coagulation testing [2, 5, 54, 55]. There
are no data to support the need for a discard tube for
specialized haemostasis assays [5]. However, due to lack
of sufficient evidence, the practice of drawing a discard
tube should still be recommended [5].
Contamination can occur through contact from micro
drops from caps with a compress, or from contact with
the interior of the tube with the syringe and from the
anticoagulant of the first tube to the second tube [4].
Contamination of coagulation assay tubes is possible if
coagulation tubes are drawn following an additive tube
like certain serum collection tubes containing clot acti-
vators [36]. In case of contamination, the results will be
erroneous and a re-collection will be necessary, leading
to a delay in subsequent medical decisions.
For platelet function assays and coagulation factors, we
suggest numbering each tube according to the sample col-
lection order. If a defect is observed on one tube, it could
be useful to check this number and verify on another tube.
Sampling process
Filling the tubes
Sodium citrated tubes must be filled up to 90% of the
nominal volume or to the mark noted on the tube if pro-
vided [41, 47]. The required ratio of sodium citrate to
whole blood is 1:9 [35, 49].
Under-filling of tubes is another important source of
error and severely affects laboratory results. An insuffi-
cient volume for testing greatly modifies the fixed blood-
to-anticoagulant ratio. Under-filling increases the
dilution of the sample due to the volume of liquid anti-
coagulant, and may increase the clotting time due to the
excess calcium-binding citrate present [4, 5, 47].
It has been reported that when tubes are drawn at less
than 89% of total fill, a clinically significant bias exists in
test results for aPTT, less than 78% for fibrinogen, and less
than 67% for coagulation factor VIII, whereas PT and acti-
vated protein C resistance remain relatively reliable even in
tubes drawn at 67% of the nominal volume [41]. Similar re-
sults were obtained in further studies [45, 56]. Instead of
rejecting a sample tube, it may be useful to note the sample
volume and to adapt the result depending on the additional
dilutional (e.g. for factor assays, fibrinogen). In case of high
haematocrit, the citrate volume may be adjusted because
this may also impact the citrate-calcium ratio. It may be
necessary to remove part of the citrate solution from the
sampling tube prior to drawing blood [35, 36, 44] (Table 2).
Mixing the samples
Following collection, blood should be adequately and
promptly mixed by three to six complete end-over-end
inversions of the tubes in order to ensure complete dis-
tribution of anticoagulant [8, 36, 47, 49, 57].
Mixing samples is an important way to prevent in-
vitro clot formation. Sometimes samples are inappropri-
ately mixed or left unmixed for a long time, thereby
avoiding full contact of the blood with the anticoagulant,
which determines partial clotting.
Vigorous shaking, vortexing or agitation of blood sam-
ples should be avoided in order to prevent inducing
haemolysis or spurious platelet and factor activation that
may result in shortened clotting times or false elevation
of clotting factor activity in specimen tests (e.g. factor
VII) [4, 8, 48, 58].
Examination of samples
When obtaining plasma for coagulation testing and prior
to processing, samples must be examined for the pres-
ence of a clot, precipitates and signs of haemolysis.
In-vitro clots may develop in samples where the blood
is slow to fill the collection container, where there is
prolonged use a tourniquet, or when considerable ma-
nipulation of the vein by the needle has occurred. These
situations must be avoided.
Several causes may induce in-vitro haemolysis, such as
slow or difficult specimen collection; prolonged tourni-
quet placing; use of incorrect devices (e.g., butterfly nee-
dles or IV catheters) or needles (e.g., small gauge
needles); unsuccessful attempts to locate the vein; in-
appropriate mixing of the sample; inappropriate centrifu-
gation speed (e.g., > 1500g); inappropriate transportation
procedures (pneumatic tube systems, duration, temperature
and humidity), … [2, 4, 5].
Table 2 Summary of key pre-analytical recommendations about
sample processing
Sample processing Blood should be adequately and promptly mixed
by 3 to 6 complete end-over-end inversions of the
tubes in order to ensure complete distribution of
anticoagulant.
Avoid vigorous shaking, vortexing or agitation of
blood samples.
Adjust the citrate volume in case of high
haematocrit (remove part of the citrate solution
from the sampling tube prior to drawing blood).
Check tubes for presence of clots, precipitates
or haemolysis.
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Haemolysis can affect some tests of haemostasis, ei-
ther because of the presence of thromboplastic sub-
stances or interference of haemoglobin pigment with
photo-optical systems [2, 49].
Lysis of the red cell membranes induces the release of
red cells contents (many intracellular enzymes, ADP …)
into plasma and may lead to activation of the plasma
sample altering coagulation parameters and activation of
other bloodlines (leucocytes, platelets).
Haemolysed samples may lead to early flow obstruction
in the PFA, presumably due to platelet activation, frag-
mentation of platelet and red blood cells and the presence
of micro-thrombi [4]. Haemolysis may lead to statistically
significant increases in PT and D-dimer. The aPTT can be
falsely prolonged or shortened and AT and fibrinogen de-
creased by in vitro haemolysis [5, 49, 59, 60].
Plasmas that are lipemic and icteric may also affect
analytic results by interfering with optical absorbance or
impeding light transmittance [49]. Mechanical and/or
electromechanical methods for clot detection should be
utilized when possible for these plasma samples [5]. Be-
cause the presence of lipid particles can still bias the
measurement for biologic interference, the CLSI cur-
rently recommends the removal of excess triglycerides
by ultracentrifugation [61]. This kind of equipment be-
ing unavailable in most routine laboratories due to high
costs and incompatibility with daily practice and because
ultracentrifugation may cause precipitation of the large
molecular proteins such as fibrinogen or factor VIII/
VWF complex, an alternative approach entails high
speed microcentrifugation (e.g., double centrifugation at
>20,000 g for 15 min) or lipid extraction by means of or-
ganic solvents or lipid-clearing agents [45, 61].
Transportation of samples
Samples should be transported non-refrigerated at ambi-
ent temperature (15–25 °C) in as short a time as possible
[8, 49, 57].
Before transport, samples should be tested regarding
identification, safety conditions and stability. Errors in
either sample identification, sample preparation before
or after transport may have an adverse effect on patients
if they are not detected on time [4, 6].
When possible, samples should be drawn directly in a
laboratory. Immediately after drawing, whole blood
should remain capped for transport both for safety rea-
sons and to minimize loss of CO2, which causes pH to
increase, leading to prolongation of PT and/or aPTT
[44]. Tubes should be stored at ambient temperature
until centrifugation [4, 5, 36]. Temperature control is
recommended in rooms where samples are kept for ana-
lysis [2]. If tubes need to be transported this should be
done with care in order to avoid unnecessary agitation.
During transportation, samples should be transferred
vertically in the shortest possible time [36].
Delays between sample collection and analysis can
cause in-vitro degradation of coagulation proteins [2].
Ideally, samples for coagulation assays should be per-
formed in the laboratory that performs the assays. If not,
specimens should be shipped from peripheral collection
facilities to the core laboratory utilizing current CLSI
guidelines (non-refrigerated at ambient temperature in
as short a time as possible, preferably within the first
hour after collection) [5, 57]. Blood samples for coagula-
tion analyses should not be shaken. Any sample that has
been dropped should be discarded. For the transport, a
box maintaining blood tubes in a steady vertical position
should be used. Transporting blood tubes in a vertical
rather than a horizontal position limits the extent of in
vitro microparticles (MP) generation [62, 63].
The temperature during transport is of special rele-
vance. Extreme temperatures should be avoided in order
to maintain sample integrity [5]. Temperatures higher
than room temperature can lead to degradation of factor
V and factor VIII [64].
The use of pneumatic tube systems (PTS) for transport
of samples is problematic and could have a significant influ-
ence on platelet function testing [8, 45]. Rapid acceleration
and deceleration may induce excessive vibration, denature
proteins and result in haemolysis, platelet activation, and
other effects [4, 35, 63]. Clinical decisions regarding platelet
function and aspirin responsiveness should not be based on
blood specimens transported by a PTS [65–68] (Table 3).
Specimen rejection
Each laboratory should have guidelines for rejection of
samples; some criteria are obligatory: inappropriate col-
lection tubes and additives, outdated tubes, error in pa-
tient identification or lack of identification, insufficient
volume, haemolysed specimens, identification of a clot,
inadequate volume, haematocrit >50% or <30% for the
Table 3 Summary of key pre-analytical recommendations about
transportation of samples
Transportation of samples Before transport, test samples regarding
identification, safety conditions and stability.
Transport samples at ambient temperature
(15–25 °C) in as short a time as possible.
Draw samples directly in a laboratory.
Immediately after drawing, whole blood
should remain capped for transport.
Temperature control is recommended in
rooms where samples are kept for analysis.
Transfer samples vertically.
Do not use pneumatic tube systems (PTS)
for transport of samples used for platelet
function analysis.
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PFA, platelet count <100,000/μL for PFA and platelet
aggregation … All samples deemed unacceptable due to
pre-analytic handling and unfulfilled transport require-
ments should be rejected [4–6, 8].
Haemolysed blood is the most common reason for reject-
ing specimens in the laboratory and, therefore, in-depth
knowledge on how to properly access the vein with the cor-
rect blood collection equipment to avoid haemolysis in the
collected specimens is a must for the phlebotomist [45].
In case of reception of an aliquot without information
about the anticoagulant used, this one must be rejected
because serum and all types of plasma have virtually iden-
tical visual appearance. Because samples that are rejected
must be recollected, which gives potential delay in patient
management, phlebotomists must be fully aware of the
common reasons why specimens are rejected (Table 4).
Centrifugation
Whenever a delay in transport is expected, it might be
advisable to perform local centrifugation and separation.
Plasma is generally prepared by centrifugation of a
whole blood sample. A temperature-controlled centri-
fuge is required for processing routine coagulation as-
says. Centrifugation should take place at room
temperature (15–25 °C) [36]. The effect of centrifugation
temperature on MP determination is still unknown [37].
It is recommended to use a centrifuge that has a rotor
with swing-out buckets to facilitate the separation of
plasma from the cellular components and to minimize
re-mixing of plasma and red cells [5, 36, 44]. It is recom-
mended to centrifuge the primary tube for coagulation
testing at 1500g for no less than 15 min with a centri-
fuge brake set off [8, 36, 47]. The centrifuge should be
validated before use, every 6 months or after modifica-
tions, in order to assure that platelet-poor plasma (PPP)
is achieved [47].
Use of the rotor brake may lead to higher residual mi-
croparticles and platelet counts, which also has an effect
on PT and fibrinogen concentration [69]. Therefore, it
seems feasible to centrifuge samples for coagulation ana-
lyses with the rotor brake set to off [4, 62]. However, ac-
cording to our personal experience, this should be
validated in appropriate studies. Our experience shows it
is important to check the absence of vibration (during
acceleration/deceleration processes) due to lack of cen-
trifuge maintenance.
Using relative centrifugal forces greater than 1500g is
not recommended as this may induce platelet activation,
haemolysis or other unwanted effects [4, 5, 47]. However,
in case of emergency, for general haemostasis parameters
performed on fresh plasma, higher centrifugation force
(greater than 1500g) and shorter time (less than 10 min)
can be used [36, 47].
Some studies have evaluated the impact of high accel-
eration centrifugation conditions on routine coagulation
testing (including especially PT, aPTT and fibrinogen; no
data were found for the thrombin time) and concluded
that rapid centrifugation does not modify results and
contributes, by decreasing duration of the pre-analytical
variable, to reduce the turnaround time for these tests
[70–76]. Note that in the REVERSE-AD study conducted
to evaluate the efficacy and safety of Idarucizumab, the
reversal agent for dabigatran [77], the centrifugation (i.e.
3 min at 1000g) used before performing dilute thrombin
time and ecarin clotting time, was not validated [78].
Both tests were used as primary endpoints and they
should thus be interpreted cautiously.
a) For analysis in platelet-poor plasma For analysis in
PPP, which is the standard material required for PT,
aPTT, fibrinogen, single coagulation factor assays, func-
tional protein S and C assays, activated protein C resist-
ance, lupus anticoagulant (LA) assays, antiphospholipid
antibody testing, thrombin generation, microparticles
measurements, homocysteine, VWF assays, tPA, PAI,
plasminogen and antiplasmin, or monitoring of unfrac-
tioned heparin therapy, and many other tests, sample
tubes require a second centrifugation and should be cen-
trifuged in capped tubes within 4 h after drawing blood
[2, 36, 37, 79]. For thrombin generation measurements,
whole blood is best centrifuged immediately, to prevent
activation or degradation of coagulation proteins. In
order to eliminate platelet debris and microparticles
from plasma, which may contribute to the variability in
thrombin generation results, a second centrifugation
step at 10,000g is recommended [2].
Double centrifugation significantly reduces the residual
amount of platelets in a sample and can be performed
to produce PPP such that the post centrifugation
plasma platelet count is less than or equal to 10x109/L.
Residual platelets in plasma have been known to affect
phospholipid-dependent coagulation tests through the ex-
posure from platelet membranes of anionic phospholipids
Table 4 Summary of key pre-analytical recommendations about
specimen rejection
Specimen rejection All samples deemed unacceptable due to
pre-analytic handling and unfulfilled transport
requirements should be rejected.
Inappropriate collection tubes and additives.
Outdated tubes.
Error in patient identification or lack of
identification.
Insufficient volume (depending on the assay). An
alternative may be to adapt the result depending
on the additional dilutional (e.g. for factor assays,
fibrinogen).
Haemolysed specimens (depending on the assay).
Identification of a clot.
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that quench LA activity. This effect leads to shorter co-
agulation time and is particularly evident, especially in
test plasmas that undergo freezing and thawing before
analysis. Adequate plasma preparation for LA testing is
an essential prerequisite for reliable diagnosis [80].
The generation of PPP should be prepared for all coagu-
lation parameters if there is a possibility that measurement
is not performed immediately after centrifugation, or if
samples are going to be frozen [5, 63].
Following initial centrifugation, the plasma is carefully
transferred to a nonactivating plastic centrifuge tube
using an automatic pipette, and then centrifuged again
for about 15 min. When pipetting, 1 cm of plasma must
remain above the buffy layer.
It is important to use an automatic pipette because
it permits slow and linear suction, unlike plastic pipettes
that pose a risk of getting a high rate of residual
platelets. The plasma is aliquoted to a secondary tube,
taking care not to include the residual platelets that
may have precipitated at the bottom of the centrifuge
tube. It has been demonstrated that a high platelet
count (>200 × 109/L) does not affect results of PT, D-
dimer, fibrinogen and aPTT assays, when samples are
tested fresh and analyzed immediately after centrifu-
gation [36, 79]. These samples should not be stored
for later analyses [47].
b) For analysis in platelet-rich plasma The preparation
of platelet-rich plasma (PRP) for platelet function ana-
lysis requires that centrifugation is performed at 200–
250 g for 10 min without application of a rotor brake
[8, 15]. These centrifugal forces appear to be the best
condition for preparing PRP for light transmission
aggregometry (LTA) studies, both in terms of the degree
of contamination of PRP by other blood cells and of plate-
let reactivity [15]. The recommendation to avoid using a
rotor brake is based on expert opinion and should be
demonstrated in appropriate studies.
Centrifugation with less than 150 g does not yield a
sufficient volume of PRP. The PRP should then be trans-
ferred to a capped polypropylene tube and a platelet
count performed.
For LTA, the platelet count of PRP samples should not
be adjusted to a standardized value by addition of autolo-
gous PPP, unless the platelet count is >600x109/L [8, 15].
However, the results of LTA studies could be inaccurate
when the platelet count in the PRP samples is lower than
150x109/L [8, 15].
All assays using whole blood or PRP need to be performed
within a maximum of 4 h after blood sampling [4, 15].
If the pre-analytical phase of the laboratory is supported
by an automated system, vigilance must be in order to test
and validate the centrifugation conditions meeting the re-
quirements of haemostasis but also the requirements of
chemistry and immunology analysis [36] (Table 5).
Storage conditions
a) conditions for the interval from sampling to analysis:
For routine coagulation testing like the PT and the
aPTT, storage of uncentrifuged samples at room
temperature up to 6 h may yield acceptable results.
However, a shorter delay is desirable. Whole blood as-
says should be performed within 4 h after blood sam-
pling and centrifugation should ideally be taken within
1 h [4, 41, 47, 49, 79, 81]. During storage, samples
should remain capped [5]. Extremes of temperature (e.g.,
both refrigerated or high) should be avoided.
Cold storage of citrated whole blood prior to centrifuga-
tion, by placing samples either in an ice bath or in refriger-
ated (2–8 °C) storage, is no longer recommended.
Improper storage of whole blood at cold temperature may
cause VWF and factor VIII values to fall below normal ref-
erence threshold levels, which may potentially lead to a
false suspicion of haemophilia A or VWD due to inappro-
priate pre-analytical handling of blood [4, 5, 25, 44, 82].
Once the blood sample has been centrifuged, plasma can
remain on the cells in a capped primary tube until testing,
or it can be aliquoted and stored in a secondary tube.
When aliquoting the plasma, care must be taken so that
the buffy coat (the layer of cells between the red cells and
plasma) is not disturbed or that this cellular component is
not introduced back into the plasma. Aliquoted plasma is
stable for 4 h when refrigerated, except for plasma for PT-
INR and PT-sec, which should not be refrigerated [2, 5, 47].
This is due to the potential for cold activation of a sample.
This may strongly influence some of the coagulation assays
Table 5 Summary of key pre-analytical recommendations about
centrifugation
Centrifugation Use a temperature-controlled centrifuge for processing
routine coagulation assays.
Validate the centrifuge before use, every 6 months or
after modifications, in order to assure that platelet-poor
plasma (PPP) is achieved.
Check the absence of vibration (during acceleration/
deceleration processes) due to lack of centrifuge
maintenance.
Centrifuge the primary tube for coagulation testing at
1500g, 15 min
In case of emergency, for PT, APTT and fibrinogen
performed on fresh plasma, higher centrifugation force
(greater than 1500g) and shorter time (less than 10 min)
can be used.
The preparation of PPP require a double centrifugation
to obtain a residual platelet count lower than 10x109/L.
Following initial centrifugation, transfer carefully the
plasma to a nonactivating plastic centrifuge tube using
an automatic pipette, and then centrifuged again for
about 15 min.
The preparation of platelet-rich plasma (PRP) for platelet
function analysis requires a centrifugation performed at
200–250 g for 10 min without application of a rotor
brake.
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and may lead to platelet activation, activation of factor VII,
which in turn can give shorter clotting times and hence
lower PT-INR and PT-sec results.
Delays in transport may affect in particular the labile
factors (FV, FVIII), leading to prolonged clotting times
and in vitro loss of factor activity [2, 83].
The time frame for analysis depends upon the stability
of the analysis, which depends on storage temperatures
and conditions. As far as the stability of citrated whole
blood, plasma on cells and aliquoted plasma is con-
cerned, more studies are needed, because there are large
differences between the conclusions of different studies
and partially missing studies.
b) short term plasma storage: PPP should be stored at
room temperature (20–25 °C) or at −80 °C until analysis.
External influences (like temperature, light …) may be of
major impact (Table 6).
Samples for PT/INR have longer stability (24 h) at
room temperature. Samples can be stored as whole
blood or stored following centrifugation [81].
Samples for aPTT testing should be stored at room
temperature and be performed using fresh plasma
within 4 h. The limited stability is largely due to time-
dependent generation or loss of labile factors, particulary
factor VIII and possibly factor V [83]. aPTT from patients
receiving unfractionated heparin (UFH) therapy has
shorter stability. For these samples, due to the variable
heparin neutralization by platelet factor 4 (PF4), the delay
before centrifugation should not exceed 1 h for a sample
collected in citrate and 4 h in CTAD. If the whole blood
sample is centrifuged within 1 h of collection, the plasma
can be left on top of the cells at room temperature up to
4 h prior to testing [83]. This applies also to fibrinolysis
parameters [35, 47, 52, 81, 83].
PT, aPTT and factor VIII tests from frozen samples
cannot be performed [4]. Freezing has an inconstant and
unpredictable effect on the results and may cause signifi-
cant elevations of aPTT, but also PT [4, 84–86]. Poorly
handled frozen material may also causes shortening of
aPTT or PT [5]. If double centrifugation is not done
when preparing a sample to be frozen this can lead to a
lysis of residual platelets upon freezing of plasma sample
and lead to shortened APTT results in heparinized pa-
tients [80].
Freezing leads to a marked decrease especially in FVIII
activity [4, 87]. In case of a factor defect observed on a
frozen sample, it is suggested to repeat the analysis on a
fresh sample.
For platelet function assays, samples should rest at
room temperature for at least 15 min before analysis.
Testing should be completed within 3 to 4 h of collec-
tion [4, 5, 8, 15].
Stability of plasma samples for special coagulation as-
says (except FVIII, anti-FXa for UFH) is largely un-
known. The shortest stability is observed for factors V
and VIII. Analyses should be performed within 3 h.
For unknown reason, protein S is labile. It has been
demonstrated that protein S activity is unstable, with a
statistically significant loss of activity demonstrated at
8 h while fibrinogen, protein C and antithrombin activity
appear to remain relatively constant when stored at
room temperature for up to 7 days [83]. VWF appears
to be stable at room temperature for 48 h [4].
Stability of the vitamin K-dependant factors has been
reported to be 24 h at room temperature [4, 5, 83, 88].
For thrombin generation, direct plasma preparation is
preferred to whole blood storage. When immediate ana-
lysis is not possible, plasma is most stable when incu-
bated at room temperature, instead of 4 °C or 37 °C,
most likely because of more activation and degradation
of coagulation proteins at these temperatures [2].
For samples coming from external laboratories, it is im-
portant to check prior to analysis whether the aliquot ex-
ternal samples (fresh or frozen) really consist of citrated
plasma. For specialized coagulation testing, most samples
are sent as frozen samples, whilst samples for routine
coagulation are more often sent as citrated blood (primary
tube). Ideally, the primary tube should be received together
Table 6 Summary of key pre-analytical recommendations about
storage conditions
Storage conditions Store samples at room temperature (15–25 °C)
until analysis.
Perform whole blood assays <4 h after blood
sampling and centrifugation <1 h.
Extremes of temperature (e.g. both refrigerated or
high) should be avoided.
Store PPP at room temperature (15–25 °C) or
at −80 °C until analysis.
If the whole blood sample is centrifuged within
1 h of collection, the plasma can be left on top
of the cells at room temperature up to 4 h
prior to testing.
Time from sampling to analysis depends on analyte:
Samples for PT/INR have longer stability (24 h) at
room temperature.
Samples for aPTT should be performed using fresh
plasma <4 h (<1 h in patients treated with
unfractionated heparin).
For platelet function assays, samples should rest at
room temperature for at least 15 min before
analysis. Testing should be completed <3–4 h
of collection.
For factors V and VIII analyses should be performed
<3 h.
Fibrinogen, protein C and antithrombin activity
appear to remain relatively constant when stored
at room temperature for up to 7 days.
Protein S activity is unstable, with a statistically
significant loss of activity at 8 h.
VWF appears to be stable at room temperature
for 48 h.
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with the aliquot tube [39]. It is not suggested to recen-
trifuge the aliquots coming from external laboratories.
c) long term plasma storage: Samples that cannot be
tested within 4 h should be centrifuged and the plasma
aliquot frozen [79] (Table 7).
For analyses that can be performed on frozen plasma,
freezing should be fast (using rapid freezing technique
like liquid nitrogen), and samples should be preferably
stored at −70 °C (or below) rather than −20 °C. Plasma
samples frozen at minus 20 °C remain stable for 2 weeks
for most coagulation parameters [36, 49]. However, it is
imperative that a frost-free freezer is not used [36, 44,
49, 83]. Plasma frozen at minus 80 °C remains stable for
6 – 18 months dependent on the parameter [47, 63, 64].
Prior to testing, frozen plasmas should be thawed rap-
idly at 37 °C (to prevent denaturing fibrinogen) and
tested immediately. This usually takes at least 3–5 min
for a 1–2 mL sample. The sample must be mixed gently
to resuspend any cryoprecipitate [49].
The samples have to be thawed at least 5 min in a water
bath at 37 °C and not at room temperature, on a bench or
in a microwave oven. After thawing they should be gently
stirred [2, 36]. After thawing, and for thrombin generation
measurements, plasma is best analysed immediately [2].
Freeze-thawing may produce phospholipid rich mem-
brane microvesicles from platelet damage which may then
mask the presence of a lupus anti-coagulant [89].
If a pathological parameter is obtained on a frozen sample,
this parameter is suggested to be re-tested on fresh plasma.
Samples may not be re-frozen. Several aliquots (suggested
volume of 500–1200 μL) should be prepared as a backup.
Frozen aliquots should be transported on dry ice [36].
Conclusion
Continuous monitoring and management of pre-analytical
errors is crucial in order to improve the quality of the pre-
analytical phase, which is essential for patient care.
Standardization efforts are essential to control and prevent
errors and to ensure the quality of exploration in haemosta-
sis. They are also necessary for all clinical laboratories
accredited by International Organization for Standardization
(ISO) document 15189. The accurate standardization of
the pre-analytical phase is of pivotal importance to achieve
reliable results of coagulation tests.
Owing to the development of large laboratory networks
and of decentralized phlebotomy services and analytical
laboratories, standardized and unequivocal procedures
and protocols are essential for sample collection, including
patient preparation, specimen acquisition, handling and
storage. These procedures are intended to prevent these
problems and to protect against complications and patient
mismanagement that could otherwise arise when speci-
mens are not collected properly in order to achieve accur-
ate and reliable coagulation measurements.
The effects of pre-analytical variables on the reliability
and consistency of screening tests is often forgotten due
to a lack of understanding and awareness. This can be
improved by educating healthcare professionals who are
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Table 7 Summary of key pre-analytical recommendations about
freezing and thawing
Freezing and thawing Do not perform PT, aPTT and factor VIII tests
from frozen samples.
Centrifuge samples that cannot be tested within
4 h and frozen the plasma aliquot.
Use rapid freezing technique (liquid nitrogen).
Store samples at −70 °C (or below) rather
than −20 °C.
Plasma samples frozen at minus 20 °C remain
stable for 2 weeks.
Plasma frozen at minus 80 °C remains stable for
6 – 18 months dependent on the parameter.
Do not re-freeze samples (but prepare a
sufficient number of aliquots).
Thaw samples rapidly at 37 °C (to prevent
denaturing fibrinogen) at least 5 min in a water
bath at 37 °C and not at room temperature,
on a bench or in a microwave oven.
Test immediately.
After thawing, mix the sample gently to
resuspend any cryoprecipitate. Do not vortex
or shake.
Do not re-frozen samples.
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